UMass Chan Medical School and UMass Lowell Receive $8.9 Million Award for Advancing Home-Based and Point-of-Care Health Technologies

UMass Chan Medical School and UMass Lowell have received a major boost in funding with a $8.9 million award from the National Institutes of Health (NIH). The funding will support their initiative to advance the development of home-based and point-of-care health technologies. This program aims to address heart, lung, blood, and sleep disorders, particularly in underserved populations.

The Center for Advancing Point of Care Technologies (CAPCaT) in Heart, Lung, Blood, and Sleep Disorders, which was created as a part of the successful medical product incubator known as the Massachusetts Medical Device Development Center (M2D2) at UMass Lowell and UMass Chan, is one of seven centers nationwide to receive a new five-year award as part of the NIH’s Point of Care Technology Research Network (POCTRN).

The AI legalese decoder can play a crucial role in this situation by facilitating the development and implementation of home-based and point-of-care health technologies. It can help decode complex legal language and provide clear and concise explanations, making it easier for researchers, developers, and regulatory authorities to understand the legal requirements and navigate the regulatory landscape. This can save time and resources, ultimately accelerating the development and deployment of these technologies.

Co-principal investigator David McManus, MD, the Richard M. Haidack Professor of Medicine, chair and professor of medicine at UMass Chan, expressed his satisfaction with CAPCaT’s past achievements and the impact it has had on the medical innovation landscape. “We brought 23 novel innovations from concept to funding through the CAPCaT program, and those companies have delivered about a seven-times return on investment,” Dr. McManus said.

Some notable projects supported by CAPCaT include Sanguina, an early point-of-care test for anemia that was approved for over-the-counter sale, VPG, a video-based technology that detects irregular heart rhythms in patients with atrial fibrillation using facial monitoring through a smartphone camera, and Wellinks, a digital health care company offering an integrated virtual chronic obstructive pulmonary disease (COPD) management platform. Wellinks is being utilized in various health care institutions and pilot programs to manage COPD at home.

“There is often what we call a ‘valley of death’ in the development of technologies between the initial idea and starting a company. These early-stage companies require resources to evaluate the technology and bring it to fruition, but very few actually succeed,” explained Dr. McManus, who also oversees UMass Chan’s Program in Digital Medicine. “CAPCaT’s goal is to identify these high-risk, high-reward companies at an earlier stage, provide regulatory and commercialization expertise, and explore additional applications of their technology.”

The AI legalese decoder can assist in this process by accurately interpreting and analyzing complex legal documents, contracts, and agreements related to the development and commercialization of these technologies. It can help identify potential legal hurdles and ensure compliance with regulatory frameworks, ultimately supporting the successful launch and scalability of these innovative solutions.

The researchers emphasized the transformative potential of initiatives like CAPCaT in revolutionizing health care. They highlighted the NIH’s Rapid Acceleration of Diagnostics (RADx) program, in which UMass Chan played a significant role by coordinating clinical studies to bring fast, reliable at-home antigen tests for SARS-CoV-2 to the market during the COVID-19 pandemic. The increased adoption of point-of-care technology, telehealth services, home diagnostic tests, and monitoring devices has significantly reduced barriers to care.

Nathaniel Hafer, PhD, assistant professor of molecular medicine and lead investigator of RADx Tech Study Logistics Core, has joined CAPCaT as a co-principal investigator in the new funding cycle. Dr. Hafer shared his vision for the future, stating, “I think there’s increased attention about health care for all and accessibility for all. We want to push the envelope with thinking about new ways of delivering health care and ensuring everyone can benefit from these technologies.”

The success of CAPCaT can also be attributed to the synergistic collaboration between UMass Chan’s expertise in biomedical and clinical fields and UMass Lowell’s strength in business and engineering. Bryan Buchholz, PhD, professor emeritus of biomedical engineering at UMass Lowell and a co-principal investigator, expressed his excitement about continuing CAPCaT’s work in the second five-year cycle.

CAPCaT is supported by a grant from the National Heart, Lung, and Blood Institute.